Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: A systematic review

Chest

Volumn 142, Issue 5, 2012, Pages 1104-1110

  Rodrigo, Gustavo J ^a   Neffen, Hugo ^b  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b 'O Alassia' Children's Hospital   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; INDACATEROL; LONG ACTING BETA 2 AGONIST; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84864588088     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2252     Document Type: Article

References (25)

1. Qaseem A, Wilt TJ, Weinberger SE, et alAmerican College of Physicians;American College of Chest Physicians; American Thoracic Society;European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease:a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med . 2011;155(3):179-191.
2. Rodrigo GJ, Nannini LJ . Tiotropium for the treatment of stable chronic obstructive pulmonary disease:a systematic review with meta-analysis. Pulm Pharmacol Ther . 2007;20(5):495-502. (Pubitemid 47077638)
3. Vogelmeier C, Hederer B, Glaab T, et alPOET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med . 2011;364(12): 1093-1103.
4. Toy EL, Beaulieu NU, McHale JM, et al . Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435-441.
5. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B;INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD:a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
6. Feldman G, Siler T, Prasad N, et al;INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration. Ann Intern Med . 2009;151(4):W65-94.
8. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6 :932-946.
9. Global strategy for the diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. Updated 2010. http://www. goldcopd.com. Accessed August 15, 2011.
10. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.
11. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-758. (Pubitemid 14121920)
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting. International Conference on Haronisation for Better Health website. http://www.ich.org/ fileadmin/Public- Web-Site/ICH-Products/Guidelines/Efficacy/ E2A/Step4/E2A-Guideline.pdf. Accessed August 10, 2011.
13. Higgins JPT, Green S . Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated 2011]. The Cochrane Collaboration;2011. www.cochrane-handbook.org. Accessed August 10, 2011.
14. Higgins JPT, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414): 557-560. (Pubitemid 37088507)
15. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-analysis. Chichester, England: John Wiley & Sons, Ltd; 2009.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
17. Altman DG, Bland JM . Interaction revisited:the difference between two estimates. BMJ. 2003;326(7382):219. (Pubitemid 36143396)
18. Donohue JF, Fogarty C, Lötvall J, et al INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium. Am J Respir Crit Care Med . 2010;182(2):155-162.
19. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12-week comparison of once daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
20. Dahl R, Chung KF, Buhl R, et al INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax . 2010;65(6):473-479.
21. Kornmann O, Dahl R, Centanni S, et al;INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD:a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
22. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719-726.
23. Cazzola M, MacNee W, Martinez FJ, et al American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials:from lung function to biomarkers. Eur Respir J. 2008; 31(2):416-469.
24. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477-492.
25. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res. 2011;12:54.